The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index, and 2 are not checked yet.
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity
Open accessAbstract
Therapies that synergistically stimulate immunogenic cancer cell death (ICD), inflammation, and immune priming are of great interest for cancer immunotherapy. However, even multi-agent therapies often fail to trigger all of the steps necessary for self-sustaining anti-tumor immunity. Here we describe self-replicating RNAs encapsulated in lipid nanoparticles (LNP-replicons), which combine three key elements: (1) an LNP composition that potently promotes ICD, (2) RNA that stimulates danger sensors in transfected cells, and (3) RNA-encoded IL-12 for modulation of immune cells. Intratumoral administration of LNP-replicons led to high-level expression of IL-12, stimulation of a type I interferon response, and cancer cell ICD, resulting in a highly inflamed tumor microenvironment and priming of systemic anti-tumor immunity. In several mouse models of cancer, a single intratumoral injection of replicon-LNPs eradicated large established tumors, induced protective immune memory, and enabled regression of distal uninjected tumors. LNP-replicons are thus a promising multifunctional single-agent immunotherapeutic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alternatively to vaccination, a pro-inflammatory tumour microenvironment can be induced by lipid nanoparticle–mRNA formulations delivering cytokines or co-stimulatory molecules33,106,161,163,214 (Table 2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,728
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Research works printed but not linked: 1
- Van Herpen, C. M. et al. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 9, 2950–2956 (2003).
Cited by
Sorted by citations
Items 101–200 of 233
Tiku, V., Kew, C., Kofoed, E. M., Peng, Y., Đikić, I., & Tan, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.870101 · Cited by 22
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death
Dong, S., Tsai, S. N., Xu, Y., Gong, F., Young, T. L., Solek, N. C., Chen, D. X. W., Healy, L., Savguira, M., Zhou, M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02045-5 · Cited by 23
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 23
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21
Zhang, D., Liu, P., Qin, X., Cheng, L., Wang, F., Xiong, X., Huang, C., & Zhang, Z. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01483a · Cited by 20
Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles
Fernandes, S., Cassani, M., Cavalieri, F., Forte, G., & Caruso, F. (2023) · Advanced Science · doi:10.1002/advs.202305769 · Cited by 20
Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery
Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20
Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles
Yan, H., Lin, G., Liu, Z., Gu, F., & Zhang, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.02.034 · Cited by 19
Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
Huayamares, S. G., Lian, L., Rab, R., Hou, Y., Radmand, A., Kim, H., Zenhausern, R., Achyut, B. R., Gilbert‐Ross, M., Lokugamage, M. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58548-1 · Cited by 17
Microbes mediated immunogenic cell death in cancer immunotherapy
Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., Tang, Y., & Leung, E. L. (2023) · Immunological Reviews · doi:10.1111/imr.13261 · Cited by 19
Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45625-0 · Cited by 18
Self-citationGamboa, L., Zamat, A. H., Thiveaud, C., Lee, H. J., Kulaksizoglu, E., Zha, Z., Campbell, N., Chan, C. S., Fábrega, S., Oliver, S. A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00968-5 · Cited by 25
Patel, E., Malkova, N. V., CROWE, D. F., Pederzoli-Ribeil, M., Fantini, D., Fanny, M., Madala, H. R., Jenkins, K. A., Yerov, O., Greene, J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0336 · Cited by 17
Chen, S., Li, K., Chen, X., Shan, L., Lin, J., & Huang, P. (2024) · Science Advances · doi:10.1126/sciadv.adn8274 · Cited by 17
Progress on angiogenic and antiangiogenic agents in the tumor microenvironment
Xu, J., & Tang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1491099 · Cited by 20
STING Protein‐Based In Situ Vaccine Synergizes CD4+ T, CD8+ T, and NK Cells for Tumor Eradication
He, Y., Hong, C., Huang, S., Kaskow, J. A., Covarrubias, G., Pires, I. S., Sacane, J. C., Hammond, P. T., & Belcher, A. M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300688 · Cited by 17
Corosolic acid derivative-based lipid nanoparticles for efficient RNA delivery
Liu, Y., Zhang, R., Yang, Y., Liu, X., & Jiang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.073 · Cited by 16
Polymer-based synthetic oncolytic virus-like nanoparticles for cancer immunotherapy
Gao, Y., Zhao, H., Zhao, J., Ma, S., Si, X., Liu, L., Qiao, R., Song, W., & Chen, X. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1841-8 · Cited by 15
Hughson, A. L., Hannon, G., Salama, N., Vrooman, T. G., Stockwell, C. A., Mills, B. N., Garrett-Larsen, J., Qiu, H., Katerji, R., Benoodt, L., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102350 · Cited by 19
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Advances in the development of lipid nanoparticles for ophthalmic therapeutics
Chen, S., Deng, Z., & Ji, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117108 · Cited by 16
Zhao, W., Zeng, C., Yan, J., Du, S., Hou, X., Zhang, C., Li, W., Deng, B., McComb, D. W., Xue, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103131 · Cited by 14
Self-citationSelf-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2
Lin, G., Yan, H., Sun, J., Zhao, J., & Zhang, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.021 · Cited by 14
Zhang, Y., Ma, F., Chen, J., Chen, Y., Xu, L., Li, A., Liu, Y., Ma, R., & Shi, L. (2024) · Advanced Materials · doi:10.1002/adma.202309927 · Cited by 13
Jiang, Y., Jiang, B., Wang, Z., Li, Y., Cheung, J. C., Yin, B., & Wong, S. H. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168888 · Cited by 15
Self-citationHou, X., Wang, C., Zhong, Y., Wang, L., Kang, D. D., Lubitz, G. S., Xue, Y., Liu, Z., Wang, S., Li, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113684 · Cited by 13
Self-citationAdvanced nanoscale delivery systems for mRNA-based vaccines
Mobasher, M., Ansari, R. A., Castejon, A. M., Barar, J., & Omidi, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130558 · Cited by 13
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 13
Interleukin-12 Message in a Bottle
Cirella, A., Berraondo, P., Trani, C. A. D., & Melero, I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3250 · Cited by 12
Lee, B., Nanishi, E., Levy, O., & Dowling, D. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061766 · Cited by 14
Engineering the Immune Adaptor Protein STING as a Functional Carrier
Sun, X., Ni, Y., He, Y., Yang, M., Tani, T., Kitajima, S., Barbie, D. A., & Li, J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100066 · Cited by 13
Advances in engineering and delivery strategies for cytokine immunotherapy
Bohmer, M., Xue, Y., Jankovic, K. E., & Dong, Y. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2208344 · Cited by 11
Self-citationShin, H. S., Kim, S., Jin, S. M., Yoo, Y. J., Heo, J. H., & Lim, Y. T. (2023) · Advanced Materials · doi:10.1002/adma.202309039 · Cited by 12
Silver, A. B., Tzeng, S. Y., Lager, M., Wang, J., Ishihara, J., Green, J. J., & Spangler, J. B. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101289 · Cited by 11
Niu, L., Jang, E., Chin, A. L., Huo, Z., Wang, W., Cai, W., & Tong, R. (2024) · Science Advances · doi:10.1126/sciadv.adk7695 · Cited by 11
Huang, H., Mu, Y., Huang, Y., Ji, B., Wang, Y., Chen, C., Chen, Y., Luo, Z., Li, S., Zhang, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59490-y · Cited by 11
Multimeric RNAs for efficient RNA-based therapeutics and vaccines
Kim, D., Han, S. W., Ji, Y., Moon, S., Nam, H., & Lee, J. B. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.052 · Cited by 11
Revitalizing Cytokine‐Based Cancer Immunotherapy through Advanced Delivery Systems
Chen, P., Paraiso, W. K. D., & Cabral, H. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300275 · Cited by 11
Applications and challenges of biomaterial mediated mRNA delivery
Fang, H., & Chen, Q. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00093 · Cited by 12
Emerging IL-12-based nanomedicine for cancer therapy
Xin, Z., Qu, S., Qu, Y., Xu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102331 · Cited by 11
Shahzad, A., Teng, Z., Yameen, M., Liu, W., Cui, K., Liu, X., Sun, Y., Duan, Q., Xia, J., Dong, Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117465 · Cited by 11
Self-citationEslami, S. M., & Lü, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.035 · Cited by 10
Application of nanomedicines in tumor immunotherapy
Gao, Z., Wan, D., Luo, M., & Wei, X. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae055 · Cited by 11
Momin, N. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.102994 · Cited by 9
Self-citationShaw, I., Boafo, G. F., Ali, Y. S., Liu, Y., Mlambo, R., Tan, S., & Chen, C. (2024) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2326091 · Cited by 9
Protocol to study the immune profile of syngeneic mouse tumor models
Miyauchi, S., Arimoto, K., Liu, M., Zhang, Y., & Zhang, D. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103139 · Cited by 8
Shifting cold to hot tumors by nanoparticle-loaded drugs and products
Ahmad, I., Altameemi, K. K. A., Hani, M. M., Ali, A. M., Shareef, H. K., Hassan, Z. F., Alubiady, M. H. S., Al‐Abdeen, S. H. Z., Shakier, H. G., & Redhee, A. H. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03577-3 · Cited by 9
Construction of novel magnetic systems for cancer immunotherapy via cancer-immunity cycle circuits
Huang, L., Zhang, Q., Long, J., Liu, Z., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.009 · Cited by 8
Unlock the sustained therapeutic efficacy of mRNA
Cao, D., Tian, M., Liu, Z., Guo, K., Peng, J., Ravichandra, A., Ferrell, C., & Dong, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113837 · Cited by 8
Self-citationYan, Q., Sun, R., Cui, Z., Zhang, J., Zhang, Y., Zhang, Q., Zhu, S., Wang, L., Li, Q., Lü, M., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101649 · Cited by 8
Ronniger, M., Aguida, B., Stacke, C., Chen, Y., Ehnert, S., Erdmann, N., Eschenburg, G., Falldorf, K., Pooam, M., Wing, A., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9100595 · Cited by 9
In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo
Kimura, K., Aicher, A., Niemeyer, E., Areesawangkit, P., Tilsed, C. M., Fong, K. P., Papp, T. E., Albelda, S. Μ., Parhiz, H., & Predina, J. D. (2025) · Vaccines · doi:10.3390/vaccines13020178 · Cited by 7
Wang, X., Fan, R., Wang, G., Han, B., Zhou, L., Tong, A., Zou, B., & Guo, G. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101345 · Cited by 7
Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7
Li, H., Lu, J., Tan, S., Jiang, T., He, X., Qiao, W., Hu, C., Dalangood, S., Lin, J., & Gui, J. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0834 · Cited by 8
Kang, B. H., Momin, N., Moynihan, K. D., Silva, M., Li, Y., Irvine, D. J., & Wittrup, K. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248903 · Cited by 7
Self-citationAdvances in Brain Delivery Systems Based on Biomimetic Nanoparticles
Li, C., Qian, J., & Chu, Y. (2022) · ChemNanoMat · doi:10.1002/cnma.202200066 · Cited by 7
The role of immune subtyping in glioma mRNA vaccine development
Guterres, A., Costa, M. A., & Neves, P. (2023) · Immunotherapy · doi:10.2217/imt-2023-0027 · Cited by 7
Lim, T. K. Y., Ritoux, A., Paine, L. W., Ferguson, L., Abdul, T., Grundy, L. J., & Smith, E. S. J. (2025) · eLife · doi:10.7554/elife.105978.3 · Cited by 9
Chemical Construction of In Situ Tumor Vaccination
Xu, P., Cheng, X., Zhang, L. W., Wang, Y., & Wang, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c09427 · Cited by 6
Zhang, G., Tu, J., Zhang, Y., He, J., Peng, G., Fan, Q., Zhang, Y., Zhang, M., Tan, H., Xu, Y., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102620 · Cited by 6
Advances in lipid nanoparticles delivering genetic medicines for solid cancers
Yang, F., & Scott, T. A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102838 · Cited by 10
Yu, J., Yu, X., Sun, X., Wang, Q., Long, S., Ren, R., Guan, Z., & Yang, Z. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.023 · Cited by 6
Surface charge-dependent cytokine production using near-infrared emitting silicon quantum dots
Chinnathambi, S., Shirahata, N., Lesani, P., Vaijayanthi, T., & Pandian, G. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-60536-2 · Cited by 6
Delivery approaches of immunomodulatory nucleic acids for cancer therapy
Hu, X., Enbar, T., & Tang, L. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103182 · Cited by 6
Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity
Silva-Pilipich, N., Beloki, U., Apaolaza, P., Igea, A., Salaberry, L., Prats-Mari, L., Rovira, E., Ondiviela, M., Gorraiz, M., Lasarte, J. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.027 · Cited by 6
RNA-lipid nanoparticle therapeutics for women’s health
Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 7
Lyu, X., Han, J., Chen, L., Zhou, Y., & Wang, W. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5762 · Cited by 6
RNA immunotherapy: revolutionizing cancer and autoimmune disease treatments
Savguira, M., Chen, D., Dong, S., & Li, B. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.06.008 · Cited by 10
Li, Z., Zhang, Z., Ma, L., Wen, H., Kang, M., Li, D., Zhang, W., Luo, S., Wang, W., Zhang, M., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202400049 · Cited by 5
Huang, F., Li, K., Chen, Z., Cui, Z., Hankey, W., Fang, K., Yan, J., Wang, H., Jin, V. X., Dong, Y., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03239-2 · Cited by 5
Self-citationZhang, F., Burghardt, T., Höhn, M., & Wagner, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060779 · Cited by 5
Kim, B., Hosn, R. R., Remba, T. K., Dye, J., Mak, H. H., Jeong, J. Y., Cornwall-Brady, M. R., Abraham, W. D., Maiorino, L., Melo, M. B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.09.642244 · Cited by 5
Self-citationYousefpour, P., Ghosh, A. R., Chawla, H., Yeung, R., Gregory, J. R., Si, K., Remba, T. K., Rodrigues, K. A., Melo, M. B., Dye, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.036 · Cited by 4
Self-citationYang, C., Zhang, L., Yang, Y., Su, M., Jiang, M., Li, J., Zhang, D., Sun, Y., Ding, D., Jia, H., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03454 · Cited by 4
Jiang, S., Li, Y., Di, W., Zhang, L., Tian, X., & Meng, F. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105159 · Cited by 4
Self-citationRecent advances in development of nano-carriers for immunogene therapy in various complex disorders.
Shahgordi, S., Oroojalian, F., Hashemi, E., & Hashemi, M. (2022) · PubMed Central · doi:10.22038/ijbms.2022.59718.13245 · Cited by 4
Alphaviruses in cancer immunotherapy
Lundstrom, K. H. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.03.011 · Cited by 4
Kepp, O., & Kroemer, G. (2020) · Nature Cancer · doi:10.1038/s43018-020-00107-2 · Cited by 4
Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigensPreprint
Gamboa, L., Zamat, A. H., Vanover, D. A., Thiveaud, C. A., Peck, H. E., Phuengkham, H., Sivakumar, A., Harris, A. M., Dahotre, S. N., Su, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.11.472238 · Cited by 4
Zhan, Y., Li, F., Wang, F., Cheng, D., He, S., Chen, M., Ding, L., & Li, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c15319 · Cited by 3
Miyake-Stoner, S. J., Maine, C. J., Chou, A. C., Dailey, G. P., Spasova, D. S., Domingo, C. C., Sparks, J., Picarda, G. G. A., Lyerly, H. K., Crosby, E. J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.026 · Cited by 3
Wang, Y., Chen, G., Wang, Y., Yao, Y., Lin, H., Wang, F., He, Y., Zhao, P., & Wang, Y. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126917 · Cited by 5
Gupta, A., Das, R., Reed, K., Jeon, T., Nguyen, Q. T. C., Rudra, A., Ge, X., Trongjit, S., Vanrobaeys, Y. S., Langer, R., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03115-2 · Cited by 6
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy
Wu, V. M., Arch, R. H., Canton, D. A., & Zhang, J. (2023) · Immunotherapy · doi:10.2217/imt-2023-0018 · Cited by 3
Ene, C. D., Nicolae, I., & Căpuşă, C. S. (2024) · Medicina · doi:10.3390/medicina60121971 · Cited by 2
Cascade amplification of therapeutic payloads for cancer immunotherapy
Li, Y., Wu, J., Li, N., Wu, M., Wang, Z., Li, J., & Zhang, L. (2025) · Communications Biology · doi:10.1038/s42003-025-08735-z · Cited by 2
Self-citationFormulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor
Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Yang, T., Zhao, D. B., & Wang, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107525 · Cited by 2
Using Controlled Drug Delivery Systems to Increase the Effectiveness of Intratumoral Immuno-oncology
Sharma, S. N., Dai, R., Morozov, F., Linderman, S. W., Laidlaw, G., Johnson, G. E., & Wehrenberg-Klee, E. P. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.09.012 · Cited by 2
Yamada, K., Suzuki, T., & Farsad, K. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.08.037 · Cited by 2
Tang, Y., Deng, X., Yi, M., Wang, D., Zheng, C., Zhao, S., & Zhao, R. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03882-1 · Cited by 2
Zhang, Y., Song, G., Niu, G., Li, R., Yuan, X., Ran, N., Hu, Y., Du, T., Chen, Y., Kang, Y., et al. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103203 · Cited by 2
Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer
Huang, F., Yuan, F., Li, K., Cui, Y., Li, L., Ye, W., Cui, Z., Yan, J., Chen, Q., Nicchitta, C. V., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01720-9 · Cited by 2
Self-citationLocal immunotherapy of cancer and metastasis
Kwon, S., & Yeo, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00018-x · Cited by 2
Nanomaterials-enabled mRNA delivery for Cancer immunotherapy
Chen, Y., Liang, S., Peng, Y., Ma, K., Yun, K., Ma, X., Hai, L., Mei, L., Wang, L., & Wang, Z. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216945 · Cited by 2
Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.30.526116 · Cited by 2
Self-citationInterleukin-35 mRNA therapy for influenza virus-induced pneumonia in mice
Li, Y., Liao, Y., Miao, Y., Yu, C., Long, J., Wu, J., Zuo, J., Zhang, Z., Dou, W., Wang, X., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177366 · Cited by 2
Self-citationWang, Y., Liu, N., Xu, C., Wang, J., Dong, L., Yang, S., & Jiang, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02626-9 · Cited by 1
Shen, A., Zhao, J., Su, Z., Wang, R., Li, Y., Zhu, C., Zhao, Q., Yu, P., Xu, Z. P., & Zhang, L. L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.021 · Cited by 1
Self-citation
Metadata
- Authors
- Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- The Ohio State University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Dong, Yizhou
- Irvine, Darrell J.
- Weiss, Ron
- ORCID
- Venue
- Nature Cancer
- Published
- 2020-08-10
- Volume
- 1
- Issue
- 9
- Pages
- 882-893
- ISSN
- 2662-1347 (ISSN-L)
- PMC
- PMC8386348
- OpenAlex
- W3047822613
- Cited by
- 233
- References
- 47
- Citations by year
- 2026: 24 · 2025: 45 · 2024: 58 · 2023: 43 · 2022: 34 · 2021: 26 · 2020: 3
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30-CA14051, CA20618)
- Howard Hughes Medical Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA20618)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM119679)
- Professor Sylvan G. Frank Graduate Fellowship
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- self-replicating RNA, IL-12, immunogenic cancer cell death, cancer immunotherapy, type I interferon response, tumor microenvironment inflammation, systemic antitumor immunity, immunological memory, intratumoral injection
- MeSH terms
- Animals, Immunotherapy, Liposomes, Neoplasms, RNA, Interleukin-12, Mice, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
